These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29930934)

  • 1. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.
    Cohen K; Weinstein AM
    Front Public Health; 2018; 6():162. PubMed ID: 29930934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
    Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
    Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.
    Weinstein AM; Rosca P; Fattore L; London ED
    Front Psychiatry; 2017; 8():156. PubMed ID: 28878698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of synthetic cannabinoids on executive function.
    Cohen K; Kapitány-Fövény M; Mama Y; Arieli M; Rosca P; Demetrovics Z; Weinstein A
    Psychopharmacology (Berl); 2017 Apr; 234(7):1121-1134. PubMed ID: 28160034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond THC: The New Generation of Cannabinoid Designer Drugs.
    Fattore L; Fratta W
    Front Behav Neurosci; 2011; 5():60. PubMed ID: 22007163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids in clinical practice.
    Williamson EM; Evans FJ
    Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic cannabinoid use among college students.
    Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
    Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis, cannabinoids, and health.
    Lafaye G; Karila L; Blecha L; Benyamina A
    Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard].
    Bonnet U; Mahler H
    Fortschr Neurol Psychiatr; 2015 Apr; 83(4):221-31. PubMed ID: 25893495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
    Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
    Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.
    Castellanos D; Gralnik LM
    World J Clin Pediatr; 2016 Feb; 5(1):16-24. PubMed ID: 26862498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cannabis use and somatic consequences].
    Franchitto N
    Rev Prat; 2020 Jan; 70(1):69-77. PubMed ID: 32877036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive and Negative Effects of Cannabis and Cannabinoids on Health.
    Cohen K; Weizman A; Weinstein A
    Clin Pharmacol Ther; 2019 May; 105(5):1139-1147. PubMed ID: 30703255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids: from pot to lab.
    Papaseit E; Pérez-Mañá C; Pérez-Acevedo AP; Hladun O; Torres-Moreno MC; Muga R; Torrens M; Farré M
    Int J Med Sci; 2018; 15(12):1286-1295. PubMed ID: 30275754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015.
    Riederer AM; Campleman SL; Carlson RG; Boyer EW; Manini AF; Wax PM; Brent JA;
    MMWR Morb Mortal Wkly Rep; 2016 Jul; 65(27):692-5. PubMed ID: 27413997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation.
    Young AC; Schwarz E; Medina G; Obafemi A; Feng SY; Kane C; Kleinschmidt K
    Am J Emerg Med; 2012 Sep; 30(7):1320.e5-7. PubMed ID: 21802885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.